Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $150.88, for a total value of $4,963,952.00. Following the sale, the chief executive officer now owns 76,026 shares of the company’s stock, valued at approximately $11,470,802.88. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Edwards Lifesciences stock traded down $0.29 during trading hours on Tuesday, reaching $149.59. The company had a trading volume of 2,091,700 shares, compared to its average volume of 1,436,873. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.31 and a quick ratio of 1.85. The stock has a market capitalization of $32.55 billion, a P/E ratio of 39.37, a price-to-earnings-growth ratio of 2.05 and a beta of 0.87. Edwards Lifesciences Corp has a 12-month low of $107.49 and a 12-month high of $175.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.05. The business had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.84 EPS. Sell-side analysts expect that Edwards Lifesciences Corp will post 4.7 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on EW shares. Guggenheim reissued a “buy” rating and set a $170.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 27th. JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a report on Friday, July 27th. Northland Securities reissued a “hold” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 27th. Citigroup raised their price objective on Edwards Lifesciences from $115.00 to $118.00 and gave the company a “sell” rating in a report on Tuesday, July 31st. Finally, Barclays started coverage on Edwards Lifesciences in a report on Monday, October 15th. They set an “underweight” rating and a $143.00 price objective on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $156.79.

A number of institutional investors have recently made changes to their positions in EW. Honkamp Krueger Financial Services Inc. purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $106,000. Private Capital Group LLC purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $112,000. Centaurus Financial Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $114,000. SRS Capital Advisors Inc. increased its stake in Edwards Lifesciences by 317.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after purchasing an additional 508 shares during the period. Finally, TLP Group LLC increased its stake in Edwards Lifesciences by 163.6% in the 3rd quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock worth $118,000 after purchasing an additional 422 shares during the period. 81.27% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Edwards Lifesciences Corp (EW) CEO Sells $4,963,952.00 in Stock” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/20/edwards-lifesciences-corp-ew-ceo-sells-4963952-00-in-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.